IDEXX Laboratories (IDXX) Stock Price, News & Analysis

Company Overview

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions. The company also operates commercial reference laboratories that provide routine and specialty testing, and offers software and connectivity platforms that deliver laboratory results, imaging and practice-management functionality to veterinary practices. In addition to companion animal diagnostics, IDEXX provides testing and monitoring solutions for dairy herd management, livestock health and water quality.

Founded in the early 1980s and based in Maine, IDEXX has grown into a multinational business with operations and customers across North America, Europe, the Asia-Pacific region and Latin America. Its customer base spans independent and corporate veterinary practices, academic and research institutions, municipal and industrial water utilities, and participants in the food supply chain. The company emphasizes recurring revenue streams from consumables and laboratory services alongside instrument sales, supported by ongoing research and development efforts to expand diagnostic capabilities and digital offerings.

IDEXX positions itself as a technology-driven diagnostics company focused on improving decision-making for animal and public health. Its strategy centers on broadening its diagnostic menu, strengthening laboratory and digital service offerings, and supporting veterinary and public health customers with integrated solutions that aim to improve clinical outcomes and operational efficiency.

Key Stats

• Today's Range: $528.02 to $540.53
• 50-Day Range: $528.68 to $648.70
• 52-Week Range: $496.61 to $769.98
• Volume: 147,847 shs
• Average Volume: 531,611 shs
• Market Capitalization: $42.66 billion
• P/E Ratio: 39.88
• Dividend Yield: N/A
• Price Target: $751.00
• Consensus Rating: Moderate Buy

IDEXX Laboratories Stock Analysis - MarketRank™

IDEXX Laboratories scored higher than 88% of companies evaluated by MarketBeat, and ranked 104th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

IDEXX Laboratories has a consensus price target of $751.00, representing about 42.1% upside from its current price of $528.68.

Amount of Analyst Coverage

IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.21%

Earnings Growth

Earnings for IDEXX Laboratories are expected to grow by 12.21% in the coming year, from $14.66 to $16.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEXX Laboratories is 38.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.37.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEXX Laboratories is 38.93, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.03.

Price to Earnings Growth Ratio

IDEXX Laboratories has a PEG Ratio of 3.11. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IDEXX Laboratories has a P/B Ratio of 26.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.66% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.77, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently increased by 0.86%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEXX Laboratories does not currently pay a dividend.

Dividend Growth

IDEXX Laboratories does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.22

News Sentiment

IDEXX Laboratories has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for IDEXX Laboratories this week, compared to 6 articles on an average week.

Search Interest

9 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

2 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,525,070.00 in company stock.

Percentage Held by Insiders

0.79% of the stock of IDEXX Laboratories is held by insiders.

Percentage Held by Institutions

87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IDXX
• CIK: 874716
• Web: www.idexx.com
• Phone: (207) 556-0300
• Fax: 207-556-4346
• Employees: 11,000
• Year Founded: 1983

Price Target and Rating

• Average Price Target for IDEXX Laboratories: $751.00
• High Price Target: $830.00
• Low Price Target: $640.00
• Potential Upside/Downside: +38.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $13.58
• Trailing P/E Ratio: 39.70
• Forward P/E Ratio: 36.87
• P/E Growth: 3.11
• Net Income: $1.06 billion
• Net Margins: 24.63%
• Pretax Margin: 30.80%
• Return on Equity: 70.87%
• Return on Assets: 32.56%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.12
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $4.30 billion
• Price / Sales: 9.91
• Cash Flow: $15.27 per share
• Price / Cash Flow: 35.39
• Book Value: $19.73 per share
• Price / Book: 27.40

Miscellaneous

• Outstanding Shares: 78,880,000
• Free Float: 78,260,000
• Market Cap: $42.64 billion
• Optionable: Optionable
• Beta: 1.58